Kornimate/medical-research-clean huggingface dataset:
recording cyclist crashes and long-term injury consequences by new smart tools

Conditions: Brief Description of the Focus of the Study: Number of Injuries to Bicyclists and Micro Mobility Users

Summary: recording cyclist crashes and long-term injury consequences by new smart tools

the recyclist project is a collaboration between research institutes from the health and transport sciences, public authorities, medical expertise and web-tool developers, and end-user organisations, and as such an excellent example of a project that promotes and supports cooperation between research groups and users of the research. three major research questions are addressed in the recyclist project: 1. what are the numbers, characteristics and locations of accidents and injuries among cyclists and e-scooter/micro mobility device users in a representative county (agder) in norway? 2. what are the consequences of injuries in terms of social and individual costs including long-term consequences with respect to recovery, disability rates etc.? 3. what are the overall health impacts of cycling, when including the more comprehensive set of positive and negative effects; and what are the economic impacts from increased cycling (in terms of cost-benefit ratios)? to answer these research questions, the investigators will develop a new digital registration tool to record accidents and injuries among cyclists and users of micro mobility devices in agder county in norway. patients will be followed up and data on medical rehabilitation, recovery and general conditions will be collected by use of questionnaires after three and twelve months. to map long-term consequences of injuries (\> 1 year), a retrospective study will be applied based on linking data from different registers containing information about health, welfare benefits and injuries.

Eligibility criteria:
inclusion criteria: * all cyclist (including micromobility devices), with recent accidents submitted to out- and in patient clinics in a well defined region of 310 000 inhabitants exclusion criteria: * no informed consent * "patients" not eligible for follow up within our region

Keywords: bicyclist injuries bicyclist accidents
evaluation of kisspeptin stimulated insulin secretion with hyperglycemic clamp

Conditions: Metabolic Disease

Summary: the goal of this study is to understand how exogenous kisspeptin affects metabolism by evaluating responses to an hyperglycemic clamp

assignment: each study subject will serve as their own control. the order of the visits will be randomized. delivery of interventions: prior to the study visit, subjects will undergo a review of their medical history and screening laboratories. during the inpatient study, the subjects will undergo a 16-hour kisspeptin infusion undergo a hyperglycemic clamp

Eligibility criteria:
* over the age of 17 * normal pubertal development * regular menstrual cycles * stable weight for previous three months * normal body mass index * blood pressure systolic bp \< 140 mm hg, diastolic \< 90 mm hg * normal hemoglobin * hemoglobin a1c \< 6.5% * bun, creatinine not elevated * ast, alt \< 3x upper limit of normal * negative serum pregnancy test exclusion criteria: * active illicit drug use, * history of a medication reaction requiring emergency medical care, * difficulty with blood draws. * history of hypertension, diabetes, heart disease, high cholesterol, cancer, or clotting disorders. * history of chronic disease that has required hospitalization * recent use of prescription medications which interfere with metabolism or reproduction (recent = within 5 half-lives of the drug) unless it is birth control * history of diabetes in a first degree relative * hyperlipidemia by fasting lipid panel
evaluate the efficacy and safety of musk pill on coronary microvascular dysfunction

Conditions: Angina Pectoris; Coronary Heart Disease; X Syndrome, Angina; Non Obstructive Coronary Artery Disease

Summary: objective to evaluate the effect of shexiang baoxin pill on myocardial ischemia in patients with coronary microvascular dysfunction (non obstructive coronary heart disease) through a randomized, double-blind, placebo-controlled clinical multicenter study.at the same time, the effects of exercise tolerance and quality of life were also observed.


Eligibility criteria:
inclusion criteria: 1. patients aged 18-80, male or female; 2. selective coronary angiography or coronary cta showed that the diameter of coronary artery ≥ 2.5mm, the degree of stenosis \< 50%, without myocardial bridge; 3. they were able to perform treadmill exercise, and the treadmill test (eet) was positive; 4. angina pectoris was found; 5. patients are willing to follow up and sign informed consent; all the above criteria should be met. exclusion criteria: 1. coronary heart disease complicated with hypertrophic cardiomyopathy; 2. there was a history of ami, pci and cabg, and myocardial bridge was found by angiography or cta; 3. patients with severe medical diseases (liver, kidney, hematopoietic system and other serious primary diseases, etc.); 4. mental disorders and mental diseases; 5. patients with pulmonary failure and nyha heart function grade iii-iv, unable to carry out exercise test; 6. contraindications of shexiang baoxin pill: forbidden for pregnant women; 7. those who have known history of allergy to shexiang baoxin pills; 8. recently, the patient has taken shexiang baoxin pill and other anti ischemic traditional chinese medicine regularly, or it contains borneol, toad venom and other ingredients in shexiang baoxin pill; 9. combined with frequent ventricular premature beats, ventricular tachycardia, atrial fibrillation, sinoatrial block, atrioventricular pathway block, left bundle branch block and right bundle branch block, which may affect the judgment of exercise ecg results; 10. researchers think that there are other factors that are not suitable to participate in the trial; if one of the exclusion criteria is met, it can be excluded.

Keywords: shexiang baoxin pill musk pill patients with coronary microvascular dysfunction
clinical characteristics and prognostic factors of patients with covid-19

Conditions: Coronavirus

Summary: as of february 17th, 2020, china has 70635 confirmed cases of coronavirus disease 2019 (covid-19), including 1772 deaths. human-to-human spread of virus via respiratory droplets is currently considered to be the main route of transmission. the number of patients increased rapidly but the impact factors of clinical outcomes among hospitalized patients are still unclear.

as of february 17th, 2020, china has 70635 confirmed cases of coronavirus disease 2019 (covid-19), including 1772 deaths. human-to-human spread of virus via respiratory droplets is currently considered to be the main route of transmission. the number of patients increased rapidly but the impact factors of clinical outcomes among hospitalized patients are still unclear.

Eligibility criteria:
inclusion criteria: * adult aged \>=18years old; diagnosed with convid19. diagnostic criteria including: laboratory (rt-pcr) confirmed sars-cov-2 infection; ct of the lung conformed to the manifestation of viral pneumonia. exclusion criteria: * near-death state (expected survival time less than 24 hours); malignant tumor; pregnancy or puerperium women; patients who refused to participant.
magnesium as an adjunct for pain treatment after surgery for thumb base arthrosis

Conditions: Thumb Osteoarthritis

Summary: a randomised controlled trial of addition to the standard pain treatment of 1000 mg oral magnesium citrate or placebo for 7 days during surgery for thumb base arthrosis. intraoperative nociception will be measured with the nol-index with a pm-200 machine.

our hypothesis is that an addition of oral 1000 mg magnesium citrate daily for 7 days starting at the day of the surgery will decrease the postoperative pain and improve the recovery after surgery. it will be given as an supplement to the regular pain treatment with acetaminophen and oxycodone that are used in our hospital and compared to a placebo. the choice of treatment will be blinded for the patient, the care providers and for the research team doing the evaluation. the pain level will be collected before surgery, postoperatively and at 14 days after surgery and by a self reporting form during the first 7 days. the patients will also report their recovery with a modified qor-15 form. qor-15 is validated in a swedish version. magnesium is shown to reduce postoperative pain in some studies that used iv magnesium sulphate. for long lasting pain conditions oral magnesium is shown to improve the patients well being and decrease their pain in some conditions. magnesium acts as a mild antagonist at the nmda-receptor. thus low levels of magnesium is thought to increase the risk of long lasting postoperative pain. therefore there are reason to expect a higher dose of magnesium supplement decreases the long lasting post operative pain.

Eligibility criteria:
inclusion criteria: * planned for surgery of thumb base arthrosis with trapeziectomy with ligament reconstruction tendon interposition. * age 18 years or older. * low anesthetic risk, asa class 1 or 2. * be able to take oral medication. * be able to read and communicate in swedish. exclusion criteria: * age under 18 years. * heartfailure, kidney failure, ischemic hearth disease. * previous neuropathic pain or complex pain syndrome. * serious psychiatric morbidity * not able to communicate in swedish * skin problems that makes the application of nol-sensor impossible.
topical plurogel pn for the treatment of mildly infected diabetic foot ulcers

Conditions: Diabetic Foot Ulcer; Infection

Summary: this is an open label study of subjects who have failed protocol pgn-1300. adult subjects (greater than 18 years old) who present with a mildly infected diabetic foot ulcer (idsa criteria) having full thickness (i.e., through the dermis but not involving joint capsule, tendon, and bone) and have failed pgn-1300. subjects must also provide informed consent and meet all other entry criteria to be enrolled and receive plurogel pn.


Eligibility criteria:
inclusion criteria: * subjects who have failed treatment on protocol pgn-1300x exclusion criteria: -

Keywords: wound ulcer infected infection
prospective clinical trial of unilateral or bilateral implantation of tecnissymfony iol in cataract patients with presbyopia

Conditions: Cataract; Presbyopia

Summary: this is to evaluate the satisfaction of patient and physician about short-distance, medium-distance, long-distance postoperative vision and eyeglass dependence, glare, and visual acuity after insertion of the tecnis® symfony or tecnis® symfony toric intraocular lens.

the patients underwent uneventful phacoemulsification and implantation of tecnissymfony®. mean absolute error (mae) at 1 month was compared in srk/t, holladay2, haigis, hoffer q, barrett universal ii, and hill-rbf formula. at postoperative 1, 4, and 12 weeks, logmar visual acuity (logmarva) at the distance (5m), intermediate (66cm), and near (40cm), and spherical equivalent (se) in manifested refraction (mr) and automated refraction (ar) were measured. wavefront aberration, contrast sensitivity test, and glare test were done at 12 weeks. the questionnaire was used to investigate glare, glasses dependency, and patient satisfaction at 12 weeks.

Eligibility criteria:
inclusion criteria: * patients with unilateral or bilateral cataract * sixteen years and older * regular corneal topography and corneal astigmatism * corneal astigmatism 0.75 diopter and less for tecnis® symfony iol, and between 1.0 and 3.62 diopter for tecnis® symfony toric iol exclusion criteria: * pregnant or nursing women * in the presence of other ocular diseases that may affect the stability of the lens capsule (pseudoexfoliation syndrome, glaucoma, traumatic cataract, malfan syndrome, etc.) * white cataract * patients who need intraocular lens outside of range * in the presence of other ocular diseases that is expected to have a poor final visual acuity of less than 20/30 after surgery (amblyopia, strabismus, keratoconus, etc.) * pupil abnormality (non-reactive pupil, tonic pupils, abnormally shaped pupils, etc.) * patients using systemic or ocular medication that affect visual acuity. * patients who had previously undergone refractive surgery. * patients participating in other clinical trials during the study.

Keywords: lenses, intraocular
a study evaluating amg 193 in combination with other therapies in participants with advanced gastrointestinal, biliary tract, or pancreatic cancers with homozygous methylthioadenosine phosphorylase (mtap)-deletion

Conditions: Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

Summary: the study aims to determine maximum tolerated dose (mtd) or recommended combination dose of the mta-cooperative prmt5 inhibitor amg 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (mtap)-deleted gastrointestinal, biliary tract, or pancreatic cancers. the study also aims to determine the safety profile of amg 193 administered in combination with other therapies in adult participants with metastatic or locally advanced mtap-deleted gastrointestinal, biliary tract, or pancreatic cancers.


Eligibility criteria:
subprotocol b inclusion: * age ≥ 18 years (or ≥ legal age within the country if it is older than 18 years). * histologically or cytologically confirmed diagnosis of metastatic and/or unresectable (locally advanced) adenocarcinoma of the pancreas. * tumor tissue (ffpe sample) or an archival block must be available. participants without archived tumor tissue available may be allowed to enroll by undergoing tumor biopsy before dosing. * homozygous mtap-deletion. * disease measurable as defined by recist v1.1. * adequate organ function as defined in the protocol. exclusion: * prior treatment with a mat2a inhibitor or a prmt5 inhibitor. * radiation therapy within 28 days of first dose. * major surgery within 28 days of first dose of amg 193. * cardiovascular and pulmonary exclusion criteria as defined in the protocol. * gastrointestinal tract disease causing the inability to take po medication, malabsorption syndrome, requirement for iv alimentation, gastric/jejunal tube feeds, uncontrolled inflammatory gastrointestinal disease (eg, crohn's disease, ulcerative colitis). * history of solid organ transplantation.

Keywords: advanced cancer methylthioadenosine phosphorylase amg 193 oncology
effects of fractional co2 laser treatment on vaginal symptoms and sexual dysfunction in women with systemic sclerosis

Conditions: Systemic Sclerosis; Vulvovaginal Signs and Symptoms; Sexual Function Disturbances

Summary: women affected by systemic sclerosis and vulvovaginal atrophy will be submitted to a cycle composed of five vaginal co2 laser treatment (smartxide2 v2lr, monalisa touch, deka, florence, italy - hi scan v2lr con sonda vaginale a 360 °, dot power 30 watt, dwell time 1000 μs, dot spacing 1000 μm smart stack 1-3, emission mode deka pulse) every 30-40 days. at 1-month follow up from the last vaginal laser treatment (6 months from baseline) vagina and sexual health will be assessed by a 1-5 likert scale, a 0-10 visual analogue scale for vulvovaginal symptoms and the female sexual function index.


Eligibility criteria:
inclusion criteria: * diagnosis of systemic sclerosis; - vulvovaginal symptoms exclusion criteria: * gynecological neoplasia; - pregnancy; - pelvic organ prolapse; - vaginal and urinary infection; - pudendal neuropathy
systematic administration of calcium and vitamin d after thyroidectomy

Conditions: Thyroid Diseases

Summary: transient hypocalcaemia consist the most common postoperative complication after thyroidectomy (10-45%). it may be mild and subclinical or cause mild or severe symptoms and may lead to longer hospital stay as well as in discomfort of the patients. for the management oral or intravenous calcium with or without vitamin d administration can be used based on the blood calcium levels and on the symptomatology. the investigators intent to study a new protocol with oral calcium and vitamin d given systematically from the day of operation to assess if this practice can minimize the rate of transient hypocalcaemia and as a consequence minimize the length of stay in the hospital.

transient hypocalcaemia consist the most common postoperative complication after thyroidectomy (10-45%). it may be mild and subclinical or cause mild or severe symptoms and may lead to longer hospital stay as well as in discomfort of the patients. for the management oral or intravenous calcium with or without vitamin d administration can be used based on the blood calcium levels and on the symptomatology. group a = control group will be managed as usual. oral or iv supplements of calcium will be giver on demand and recorded according to the clinical picture or the biochemical hypocalcaemia. group b= study group will be given systematically from the day of operation a scheme with oral calcium in the form of 1000ca++mg/tab and oral alfacalcidol in the form of 0.5 micrograms/tb the patients will receive one tablet three times a day oral calcium (3g/d) and 2 tablets , two times a day alfacalcidiol (2 micrograms/d) for the first 5 days. afterwards they will be taking 2 tablets a day of oral calcium ( 2g) and 2 tablets a day alfacalcidiol (1micrograms/d) for another 10 days ( total 15 days) the investigators intent to minimize the immediate transient hypocalcaemia rate and give time to the parathyroids which may have been bruised or have compromised function initially to recover by day 15. the 1st and 2nd postoperative day the invastigators are going to take blood samples and assess the 25 hydroxy vit d, the parathyroid hormone (pth) and the ca++. the investigators will also assess the calcium levels after the first week and if necessary ( in cases with longstanding hypocalcaemia ) in later day. the patients will be discharged from the hospital the day after the operation provided the calcium levels are within normal range and they are completely asymptomatic. in case of symptoms after the discharge the patients will be managed accordingly and this will be recorded in the records of each patient

Eligibility criteria:
inclusion criteria: * thyroid pathology only * no calcium metabolism problems * total / near total thyroidectomy exclusion criteria: * renal failure, * secondary hyperparathyroidism, * primary hyperparathyroidism, * thyroid lobectomy, * thyroid reoperation
evaluating a low-literacy discharge medication education tool

Conditions: Congestive Heart Failure; Coronary Artery Disease

Summary: recent studies have demonstrated that patients sub-optimally understand hospital discharge medication instructions health literacy has been shown to be an important factor in patient understanding of medical information , and following medication instructions. the primary aim of this project is to test the efficacy of a low-literacy discharge medication education tool on medication adherence, and patient knowledge and understanding of inpatient discharge medications, in a low-income population with low health literacy levels. this evaluation is a prospective trial with patients randomly assigned to either receiving this tool or receiving the current standard of care. given the complexity of the discharge medication regimen for the conditions of congestive heart failure (chf) and coronary artery disease (cad), and the proven effectiveness of these medications in the post discharge period, this trial will focus on the subpopulation of patients hospitalized with these two conditions.


Eligibility criteria:
inclusion criteria: patient inclusion criteria will be: * 18 years of age or greater * admission to the internal medical or cardiology services at lac/usc medical center * discharge directly from the medical service to home * during admission, being evaluated or treated for congestive heart failure or coronary artery disease. patient exclusion criteria : * moderate or severe cognitive dysfunction * severe psychiatric disability such that the patient has, or there is an application for, a conservator, or any psychiatric illness with current psychotic features * not having speaking proficiency in either english or spanish language. * if the patient was previously enrolled in the study on a prior hospitalization, he or she will also be excluded. nurse inclusion criteria: * performing the patient education at hospital discharge for a patient enrolled in the study
influencing factors of the diagnostic accuracy of novel coronary functional evaluation methods

Conditions: Coronary Heart Disease

Summary: in this study, patients were retrospectively included, univariate and multivariate analysis of factors affecting their diagnosis inconsistencies was performed, and a new diagnostic model was constructed by logistic regression.

the evaluation of coronary function is becoming more and more important in the guidelines, in which coronary flow reserve (ffr) is the gold standard for diagnosis, but its measurement process requires the application of adenosine, vasodilator, etc. some patients cannot be measured because of asthma and low blood pressure. a new instantaneous wave-free ratio (ifr), contrastive flow reserve fraction (cffr) and quantitative flow fraction (qfr) have been developed for the evaluation of coronary function. however, in some patients, the new coronary function evaluation methods were inconsistent with ffr. in this study, patients were retrospectively included, univariate and multivariate analysis of factors affecting their diagnosis inconsistencies was performed, and a new diagnostic model was constructed by logistic regression.

Eligibility criteria:
inclusion criteria: * age above 18 and below 80 years old, regardless of gender; * ffr was detected by coronary angiography; * the coronary angiography images were clear, meeting the requirements of qfr analysis or detecting ifr, cffr, and resting pd/pa during the operation. exclusion criteria: * 1) coronary artery bypass graft (cabg); * 2) atrial fibrillation or flutter; * 3) left or right coronary opening lesions; * 4) pregnancy or breastfeeding.
weight loss and exercise in physically limited obese elderly subjects

Conditions: Obesity; Frailty; Elderly

Summary: the overall purpose of this research is to determine the effect of weight loss and physical training on quality of life, physical function, metabolism, bone strength, body fat and muscle mass.

obesity causes serious medical complications and impairs quality of life. moreover, in elderly persons, obesity can lead to frailty because of decreased strength, joint function, balance and mobility associated with aging. the primary objective of this study is to evaluate the effect of weight loss and physical training on physical function, body composition, metabolism and quality of life in frail, obese elderly men and women. subjects are randomized to either control or 10% weight loss plus physical training.

Eligibility criteria:
inclusion criteria: * obese (bmi 30 or greater) elderly (age 65 years or older) frailty exclusion criteria: * major chronic disease or any condition that would interfere with exercise or dietary restriction, in which exercise or dietary restriction are contraindicated, or that would interfere with interpretation of results. examples include cardiopulmonary disease, unstable disease, severe orthopedic or neuromuscular impairments, dementia, history of malignancy during the past 5 yr, current use of bone acting drugs.

Keywords: obesity, aging, frailty, exercise, weight loss
efficacy of keppra in acute alcohol related seizure control--a pilot study

Conditions: Seizure, Alcohol Related

Summary: pilot study to evaluate efficacy of keppra (levetiracetam) for seizure control in patients with alcohol related seizures.


Eligibility criteria:
inclusion criteria: * no trauma * not pregnant * no other cause for seizure (hypoglycemia, cns causes, trauma) * good family support * working telephone contact exclusion criteria: * pregnancy * renal failure (creatine \> 2mg/dl * fever or illness * hypotension * any trauma

Keywords: alcohol seizure